首页 | 本学科首页   官方微博 | 高级检索  
检索        

晚期糖基化终末产物与股骨头坏死进展的相关性研究
引用本文:庞凤祥,陈晓俊,何晓铭,沈莹珊,杨帆,龚水帝,陈立新,李伟峰,方斌,何伟,魏秋实.晚期糖基化终末产物与股骨头坏死进展的相关性研究[J].中国全科医学,2020,23(23):2913-2917.
作者姓名:庞凤祥  陈晓俊  何晓铭  沈莹珊  杨帆  龚水帝  陈立新  李伟峰  方斌  何伟  魏秋实
作者单位:1.510405广东省广州市,广州中医药大学第一临床医学院 2.510405广东省广州市,广州中医药大学第一附属医院三骨科 3.510405广东省广州市,广州中医药大学第一附属医院五骨科 4.510405广东省广州市,广州中医药大学髋关节研究中心
*通信作者:魏秋实,副教授;E-mail:weiqshi@126.com
注:何伟、魏秋实现工作单位是广州中医药大学第三附属医院关节骨科
基金项目:国家自然科学基金面上项目(81873327,81573996,81473696);广东省科技厅-广东省中医药科学院联合科研专项项目(2016A020226028);广东省自然科学基金资助项目(2017A030313698)
摘    要:背景 股骨头坏死(ONFH)是骨科临床难治性疾病,由于诊断不及时,塌陷进程快,很多患者不可避免地要面临人工全髋关节置换术的结局,寻找科学诊断早期ONFH的方法具有非常重要的现实意义。目的 分析国际骨循环学会分期(ARCO)Ⅱ~Ⅳ期ONFH患者的血浆晚期糖基化终末产物(AGEs)水平,研究其与ONFH发展进程的相关性。方法 2016年6-12月随机选取广州中医药大学第一附属医院三骨科住院治疗的ONFH患者为试验组,广州中医药大学第一附属医院体检中心进行体检的健康成年人为对照组,收集试验组患者的影像资料,按ARCO标准分为ARCO Ⅱ期、ARCO Ⅲ期、ARCO Ⅳ期。使用酶联免疫吸附测定(ELISA)检测所有研究对象的AGEs水平,分析两组间、试验组内不同坏死原因、不同ARCO分期及塌陷前后患者的AGEs水平。结果 试验组AGEs水平〔(2.87±0.73)mg/L〕高于对照组〔(2.33±0.94)mg/L〕(t=3.692,P<0.001)。不同ARCO分期、塌陷前后、病因ONFH患者AGEs水平比较,差异均有统计学意义(P<0.05);其中ARCO分期Ⅱ期AGEs水平低于Ⅳ期,创伤性(T)病因患者AGEs水平高于酒精性(AI)、激素性(SI)、特发性(ID)(P<0.05)。Spearman相关性分析结果显示,AGEs水平与ARCO分期呈正相关(rs=0.274,P=0.007)。ROC曲线下面积为0.651(0.567,0.729),AGEs水平切点为2.419 mg/L时,灵敏度为72.45%,特异度为59.09%。结论 AGEs与ONFH的进展过程密切相关,对于诊断ONFH及病情监测具有一定参考价值。

关 键 词:股骨头坏死  晚期糖基化终末产物  ARCO分期  诊断  生物标志物  病情监测  灵敏度  特异度  

Correlation between Advanced Glycation End Products and Progression of Osteonecrosis of the Femoral Head
PANG Fengxiang,CHEN Xiaojun,HE Xiaoming,SHEN Yingshan,YANG Fan,GONG Shuidi,CHEN Lixin,LI Weifeng,FANG Bin,HE Wei,WEI Qiushi.Correlation between Advanced Glycation End Products and Progression of Osteonecrosis of the Femoral Head[J].Chinese General Practice,2020,23(23):2913-2917.
Authors:PANG Fengxiang  CHEN Xiaojun  HE Xiaoming  SHEN Yingshan  YANG Fan  GONG Shuidi  CHEN Lixin  LI Weifeng  FANG Bin  HE Wei  WEI Qiushi
Abstract:Background Osteonecrosis of femoral head(ONFH) is a refractory orthopedic disease.Due to delayed early diagnosis and rapid collapse process,many patients may inevitably undergo total hip arthroplasty.Therefore,it is of great practical significance to find a scientific method to diagnose ONFH.Objective To analyze the plasma advanced glycation end products(AGEs) in patients with ONFH(ARCOⅡ-Ⅳ) and to study its correlation with the development of ONFH.Methods ONFH inpatients(consisting of ARCO Ⅱ,Ⅲand Ⅳ based on imaging data) and healthy adult physical examinees were recruited from No.3 Orthopaedic Department,and Physical examination Center,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,respectively,during June to December 2016.ELISA-detected plasma AGEs were compared between ONFH inpatients and healthy controls,and were compared in ONFH inpatients by causes of ONFH,ARCO stage,pre- and post-collapse stages.Results The mean plasma AGEs concentration in ONFH inpatients〔(2.87±0.73)mg/L〕 was greater than that of the healthy controls〔(2.33±0.94)mg/L〕(t=3.692,P<0.001).The AGEs concentration varied significantly among ARCOⅡ,Ⅲand Ⅳ patients(P<0.05).Those with ARCOⅡshowed lower mean AGEs concentration than those with ARCOⅣ(P<0.05).The AGEs concentration also varied significantly among the patients either at pre-collapse or post-collapse stage of ONFH(P<0.05).Furthermore,the AGEs concentration changed significantly according to the causes of ONFH(P<0.05).In particular,patients with trauma-induced ONFH had higher mean AGEs concentration than those with alcohol-induced,steroid-induced or idiopathic ONFH(P<0.05).According to the results of Spearman correlation analysis,AGEs concentration was positively correlated with ARCO stage(rs=0.274,P=0.007).ROC curve analysis showed that the AUC of AGEs in idnetifying the collapse of ONFH was 0.651(0.567,0.729),with 72.45% sensitivity and 59.09% specificity when the cut-off value was determined as 2.419 mg/L.Conclusion Plasma AGEs concentration is closely related to the progress of ONFH,which may be used as a reference for diagnosis of ONFH and disease monitoring.
Keywords:Femur head necrosis  Advanced glycation end products  ARCO staging  Diagnosis  Biomarkers  Disease monitoring  Sensitivity  Specificity  
点击此处可从《中国全科医学》浏览原始摘要信息
点击此处可从《中国全科医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号